The prostate cancer treatment market, valued at USD 14.01 billion in 2024 and projected to reach USD 31.60 billion by 2034 at a CAGR of 8.5%, is undergoing a structural transformation driven by segment-specific advancements in drug development, radiation modalities, and surgical interventions. Market segmentation reveals distinct performance patterns across therapy types—hormonal therapies, chemotherapy, immunotherapy, targeted radiopharmaceuticals, and minimally invasive surgical techniques—each responding differently to shifts in clinical practice, pricing pressures, and technological maturity. Hormonal therapies remain
Synes godt om
Kommentar
Del
